We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s tentative agreement with drug and biotechnology companies to accept fees in exchange for quicker reviews of direct-to-consumer (DTC) ads is prompting criticism from industry observers who believe the plan is both a conflict of interest and a violation of the First Amendment.